Why does Pharma Need to Relook at its Patient Engagement and Support Strategies?

Why does Pharma Need to Relook at its Patient Engagement and Support Strategies?

Recently, I was reading Luca Dezzani’s article “Patient Engagement: A Key Element in Pharmaceutical Marketing Strategy.” The article prompted me to think about how pharma companies continue to think about and discuss the idea of Patient Engagement, and.... Read More »

Building Regulatory Affairs: Efficiency Quadrant that Drives Spend

Building Regulatory Affairs: Efficiency Quadrant that Drives Spend

Best Practices, LLC has recently completed “Benchmarking Regulatory Affairs Staffing & Performance Excellence in Medical Devices,” a new operational benchmarking study. After analyzing the data and probing the experience of 30 regulatory affairs (RA).... Read More »

Blockbuster Launch Evolution: Learning to See the Market in Different Wavelengths and Perspectives (Part 2)

Blockbuster Launch Evolution: Learning to See the Market in Different Wavelengths and Perspectives (Part 2)

One of the areas within the Pharmaceutical and related industries which has the main goal of seeing market opportunities is the Market Research function. Despite this, many organizations’ Market Research groups do not have 20/20 vision. Read More »

New Series: Blockbuster Pharmaceutical Drugs Launch Evolution (Part-1)

New Series: Blockbuster Pharmaceutical Drugs Launch Evolution (Part-1)

At Pharma CI Conference 2015 in New Jersey, Best Practices, LLC’s CEO, Chris Bogan discussed the topic: Blockbuster Drugs Launch Evolution: Mapping Market - Entry Changes That Cause New Products to Stumble or Soar.... Read More »

Relationships Matter: To be Effective, Medical Information Groups in Pharmaceutical Companies Must Forge Collaborative Relationships with other Internal Groups such as Legal

Relationships Matter: To be Effective, Medical Information Groups in Pharmaceutical Companies Must Forge Collaborative Relationships with other Internal Groups such as Legal

Within the pharmaceutical sector, medical information groups shoulder great responsibilities. The principal role of medical information groups, which are typically part of the medical affairs organization, is responding to questions about products from external groups such as physicians. Read More »

Achieving Better Advocacy Group Relationships a Critical Piece of Resurgent Disease State Awareness Drive in Pharmaceutical Industry

Achieving Better Advocacy Group Relationships a Critical Piece of Resurgent Disease State Awareness Drive in Pharmaceutical Industry

When it comes to informing physicians and patients about new therapies, disease awareness programs have experienced a rebirth in the pharmaceutical industry. Read More »

How Can Pharma Leverage the Health Outcomes Liaison Function for Maximum Impact?

How Can Pharma Leverage the Health Outcomes Liaison Function for Maximum Impact?

With the shift toward evidence-based medicine and value-based pricing in the health care industry, bio-pharmaceutical organizations have turned to Health Outcomes Liaisons (HOLs) to serve as a scientific bridge with payer organizations, thought leaders, and other important decision makers. Read More »

 

Relationships Matter: To be Effective, Medical Information Groups in Pharmaceutical Companies Must Forge Collaborative Relationships with other Internal Groups such as Legal

Within the pharmaceutical sector, medical information groups shoulder great responsibilities. The principal role of medical information groups, which are typically part of the medical affairs organization, is responding to questions about products from external groups such as physicians. While this

Achieving Better Advocacy Group Relationships a Critical Piece of Resurgent Disease State Awareness Drive in Pharmaceutical Industry

When it comes to informing physicians and patients about new therapies, disease awareness programs have experienced a rebirth in the pharmaceutical industry. For decades, disease awareness campaigns were a part of the playbook for educating physicians and patients about new

How Can Pharma Leverage the Health Outcomes Liaison Function for Maximum Impact?

With the shift toward evidence-based medicine and value-based pricing in the health care industry, bio-pharmaceutical organizations have turned to Health Outcomes Liaisons (HOLs) to serve as a scientific bridge with payer organizations, thought leaders, and other important decision makers. It

Digital Marketing Leaders Discuss Top Tools & Channels for Enhancing Product Launch

Each quarter, the Best Practices Digital Marketing Consortium convenes a virtual roundtable meeting to bring together life-sciences executives to discuss successes, failures and new opportunities to use digital marketing to transform the bio-pharma customer engagement model. Our most recent meeting,

“Troubleshooting” a Key Challenge of the Global Branding Process for New Bio-Pharma Products: Alignment Across Geographies

In the bio-pharmaceutical industry, it is no secret that different regions of the world have diverse regulatory and cultural environments. What is less apparent is that given these regional regulatory and cultural differences, pharmaceutical companies can have an effective global

Pharma Executive Talks Timing, Targeting and Trouble for Disease State Awareness Campaigns

In the pharmaceutical sector, disease state awareness campaigns are one of the few ways to reach patients and physicians before a product is approved. In essence, they set the table for future marketing efforts at product launch and post-launch. While

Why does Pharma Need to Relook at its Patient Engagement and Support Strategies?

Recently, I was reading Luca Dezzani’s article “Patient Engagement: A Key Element in Pharmaceutical Marketing Strategy.” The article prompted me to think about how pharma companies continue to think about and discuss the idea of Patient Engagement, and ultimately what

Building Regulatory Affairs: Efficiency Quadrant that Drives Spend

Best Practices, LLC has recently completed “Benchmarking Regulatory Affairs Staffing & Performance Excellence in Medical Devices,” a new operational benchmarking study.  After analyzing the data and probing the experience of 30 regulatory affairs (RA) organizations from large and complex companies

5 Important Trends Shaping Pharma Business in 2016

In a sector as fast-changing as biopharmaceuticals, it’s important to look beyond today’s hot topics to identify the long-term factors which are really driving change in the industry. From a list that could include a hundred headline-grabbing trends, we’ve pinned

Blockbuster Launch Evolution: Learning to See the Market in Different Wavelengths and Perspectives (Part 2)

One of the areas within the Pharmaceutical and related industries which has the main goal of seeing market opportunities is the Market Research function. Despite this, many organizations’ Market Research groups do not have 20/20 vision. Much like many animals

New Series: Blockbuster Pharmaceutical Drugs Launch Evolution (Part-1)

Take a look at the slide below and see if you can answer which of the 5 drugs had a peak sales year of $13.7 billion. The answer? – Lipitor While Lipitor sold a gigantic $13.7 billion in their peak sales year,

Hotspots in Biopharma Digital Marketing Innovation

The rapid growth of digital, mobile and related technologies has transformed the global communications paradigm, and with it, changed the ways in which consumers and professionals access information. In case of the biopharmaceutical and medical device industry, the development of

Adopting the New Patient Journey Framework for Marketing

Marketing within the healthcare industry has been rapidly changing due to the growing influence of patients. Physicians are no longer the main focus in marketing when trying to determine market access and product launch success. Because patients are becoming more